Sunshine Biopharma, Inc.
SBFMAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Aegis Capital | maintain | Buy | Oct 8, 2025 |
| Aegis Capital | maintain | Buy | Dec 5, 2024 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-3.40| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-23.00 | $-24.00 | $9.3M | $8.7M |
| May 13, 2026 | $-2.50 | $-1.60 | $8.1M | $9.2M |
| Apr 3, 2026 | $-3.00 | $-2.70 | $8.6M | $10.0M |
| Nov 13, 2025 | $-1.90 | $-1.30 | $9.4M | $11.1M |
| Aug 12, 2025 | $-3.90 | $-1.10 | $9.4M | $11.2M |
| May 15, 2025 | $-4.40 | — | $8.9M | — |
| Mar 31, 2025 | $-10.10 | $0.10 | $9.6M | $12.5M |
| Nov 5, 2024 | $-9.40 | $-5350.00 | $8.4M | $11.8M |
News
FORT LAUDERDALE, FL / ACCESS Newswire / October 22, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one for twenty reverse split of its common stock, effective at market open on October 26, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
Sunshine Biopharma, Inc. (NASDAQ: SBFM - Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 131,478 shares, an increase of 461.6% from the September 15th total of 23,410 shares. Approximately 3.1% of the shares of the stock are short sold. Based
$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gr…
FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable …
Sunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataIntelo Commercial rollout supported by Nora Pharma's established Canadian distribution network, further expanding Sunshine Biopharma's generic prescription drug portfolio FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biophar…
Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and preferential lung enrichment across multiple species FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in oncology and antivirals, …
FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.
K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liver cancers Next phase will combine K1.1 mRNA with a cancer vaccine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical compan…
Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026 FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic a…